---
$id: https://graph.org.ai/products/commodity/51131742
$type: Product
source: UNSPSC
code: "51131742"
title: "Triflusal"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Triflusal

**UNSPSC Code**: 51131742
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiplatelet agent with the molecular formula C10H7F3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Z0YFI05OO, chemically known as 2,4-cresotic acid, alpha,alpha,alpha-trifluoro-, acetate but generally known as triflusal, which bears US NIH Compound Identifier 9458. European Medicines Agency schedules Triflusal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11292MIG. The term TRIFLUSAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules triflusal in its Anatomical Therapeutic Chemical (ATC) Classification. TRIFLUSAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule triflusal under HS 29182980 and SITC 51394. As of Q4 2014, TRIFLUSAL remains the US FDA Preferred Term for this commodity. Triflusal bears US NLM identifiers UMLS ID C0077126 and NCI Concept Code C76407. SMILES: CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O.

